Anbio Biotechnology (NNNN) stock
NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$3.65−0.23 (-5.93%)
Close on Nov 17, 2026Market cap $525.20MP/E 24.8Yield –
Anbio Biotechnology r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $201.31K, down 55.7% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.31K | -55.7% |
| FY2024 | Dec 31, 2024 | $454.23K | +237.2% |
| FY2023 | Dec 31, 2023 | $134.70K | -32.6% |
| FY2022 | Dec 31, 2022 | $200.00K | – |
See a number that looks wrong?